886 | wileyonlinelibrary.com/journal/jvh J Viral Hepat. 2020;27:886–895. © 2020 John Wiley & Sons Ltd Received: 12 March 2020 | Accepted: 30 March 2020 DOI: 10.1111/jvh.13311 ORIGINAL PAPER High sustained viral response rate in patients with hepatitis C using generic sofosbuvir and daclatasvir in Phnom Penh, Cambodia Meiwen Zhang 1,2 | Daniel O’Keefe 1,3 | Momoko Iwamoto 1,2 | Kimchamroeun Sann 1 | Antharo Kien 1 | Vithurneat Hang 1 | Cecile Brucker 1 | Pascal Jolivet 1 | Sovann Ly 4 | Dimanche Chhit 5 | Suna Balkan 1 | Tonia Marquardt 1 | Mickael Le Paih 1 | Jean-Philippe Dousset 1 1 Médecins Sans Frontières-France, Phnom Penh, Cambodia 2 Epicentre, Paris, France 3 Burnet Institute, Melbourne, Australia 4 Department of Communicable Disease Control, Ministry of Health, Phnom Penh, Cambodia 5 Hepato-Gastro Department of Cambodia- China Friendship Preah Kossamak Hospital, Phnom Penh, Cambodia Correspondence Meiwen Zhang, Médecins Sans Frontières- France, #205, Street 132, Sangkat Teuklaak1, Khan Toulkork, PO Box 845, Phnom Penh, Cambodia. Email: meiwen.zhang@hotmail.com Funding information Funding for the study was provided by Unitaid (https://unitaid.org/) and Médecins Sans Frontières (MSF, https:// www.msf.org/). A grant from Unitaid (SPHQ14-LOA-217) financed parts of this implementation. Meiwen Zhang, Daniel O’Keefe, Momoko Iwamoto, Jean-Philippe Dousset, Kimchamroeun San, KienAntharo, Vithurneat Hang, Cecile Brucker, Pascal Jolivet, Mickael Le Paih, Tonia Marquardt, Suna Balkan were employed by MSF, and participated in planning the study, carrying out the research, and writing the report. Abstract Safe and efficacious pan-genotypic direct-acting antiviral (DAA) regimens, such as sofosbuvir and daclatasvir (SOF + DCV), facilitate simplified models of care for hep- atitis C virus (HCV). However, in Cambodia access to HCV testing and treatment has typically been low. In response, Médecins Sans Frontières (MSF) implemented a HCV testing and treatment pilot project in Phnom Penh, Cambodia in 2016. This project provides the first real-world evidence of SOF + DCV effectiveness across a large patient cohort using a simplified care model in Cambodia. Patients treated with SOF + DCV from September 2016 to June 2019 were included in the analy- sis. Medical standard operational procedures (SOPs) were simplified significantly across the study period. Treatment effectiveness was assessed by sustained viral response at 12 weeks post-treatment (SVR12) according to a modified intention-to- treat methodology. Treatment safety was assessed by clinical outcome and occur- rence of serious and nonserious adverse events (S/AE). Of 9158 patients, median age was 57 years and 39.6% were male. At baseline assessment, 27.2% of patients had compensated cirrhosis and 2.9% had decompensated cirrhosis. Genotype 6 was predominant (53.0%). Among patients analysed according to modified intention to treat (n = 8525), treatment effectiveness was high, with 97.2% of patients achiev- ing SVR12. Occurrence of SAE was low (0.7%). Treatment effectiveness and safety was not affected by the iterative simplification to treatment modality. In conclusion, in this large treatment cohort in Phnom Penh, Cambodia, the SOF + DCV regimen showed high rates of treatment effectiveness and safety across patient sub-groups and during progressive simplification. KEYWORDS Cambodia, Daclatasvir, Hepatitis C, Sofosbuvir, SVR12